Артериальная гипертензия, сахарный диабет 2 типа и фибрилляция предсердий как самостоятельная медицинская проблема
https://doi.org/10.18705/1607-419X-2011--2-
Аннотация
Об авторах
А. В. БарсуковРоссия
Т. С. Свеклина
Россия
М. С. Таланцева
С. Б. Шустов
Россия
Список литературы
1. Marchetti P., Coppelli A., R. Giannarelli. Pathophysiological links between diabetes and heart disease // Medicographia. - 2007. - Vol. 29, № 3. - P. 213-219.
2.
3. Kannel W.B., Wolf P.A., Benjamin E.J., Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates // Am. J. Cardiol. - 1998. - Vol. 82, № 8A. - P. 2N-9N.
4.
5. Wild S., Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes; estimates for year 2000 and projections for 2030 // Diabetes Care. - 2004. - Vol. 27, № 5. - P. 1047-1053.
6.
7. Amar J. Patients with resistant hypertension // J. Hypertens. - 2007. - Vol. 25, № 1. - P. S3-S6.
8.
9. Карпов Ю.А. Артериальная гипертония у больных сахарным диабетом: основные направления лечения // Метаболический синдром. - 2001. - Т. 9, № 24. - С. 1132-1136. 6.
10.
11. Diabetes Atlas, 3rd edition. International Diabetes Federation, 2006. - 220 р. 6.
12.
13. International Diabetes Federation: Diabetes Atlas third edition / J. Hypertens. - 2001. - № 19. - P. 1167-1176. - [http://www.eatlas.idf.org/media/2006] [Electronic].
14.
15. Кактурский Л.В. Внезапная сердечная смерть: современное состояние проблемы // Арх. патологии. - 2005. - Т. 67. - С. 8-11.
16.
17. Kаntachuvessiri A. Pulmonary veins: Preferred site for catheter ablation of atrial fibrillation // Heart and Lung. - 2002. - Vol. 31, № 4. - P. 271-278.
18.
19. Prystupa A., Łopatyński J., Mieczkowska J. Atrial fibrillation and its association with type 2 diabetes // Ann. Universitat is Mariae Curie - Skłodowska. - 2008. - Vol. LXIII, № 2, 9. - P. 53-57.
20.
21. Kannel W.B., Benjamin E.J. Status of the epidemiology of atrial fibrillation // Med. Clin. North. Am. - 2008. - Vol. 92, № 1. - P. 17-40.
22.
23. Healey J.S., Connolly S.J. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target // Am. J. Cardiol. - 2003. - Vol. 91, № 10A. - P. 9G-14G.
24.
25. Weber K.T. Targeting pathological remodeling: concepts of cardioprotection and reparation // Circulation. - 2000. - Vol. 102, № 12. - P. 1342-1345.
26.
27. Verdecchia P., Reboldi G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Reboldi%20G%22%5BAuthor%5D>., Gattobigio R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gattobigio%20R%22%5BAuthor%5D>. et al. Atrial fibrillation in hypertension: predictors and outcome // Hypertension. - 2003. - Vol. 41, № 2. - P. 218-223.
28.
29. Ciaroni S., Cuenoud L., Bloch A. Clinical study to investigate the predictive parameters for the onset of atrial fibrillation in patients with essential hypertension // Am. Heart. J. - 2000. - Vol. 139, № 5. - P. 814-819.
30.
31. Krahn A.D., Manfreda J., Tate R.B., Mathewson F.A., Cuddy T.E. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba follow-up study // Am. J. Med. - 1995. - Vol. 98, № 5. - P. 476-484.
32.
33. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. - 2005. - Vol. 45, № 5. - P. 712-719.
34.
35. Du X., Ninomiya T., de Galan B. et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study // Eur. Heart. J. - 2009. - Vol. 30, № 9. - P. 1128-1135.
36.
37. Свеклина Т.С. и др. Лабораторные маркеры кардиоваскулярного прогноза у пациентов с артериальной гипертензией в сочетании с сахарным диабетом второго типа и фибрилляцией предсердий // Вестн. Чувашского государственного педагогического ун-та им. И.Я. Яковлева. - 2010. - Т. 68, № 4. - С. 12-18.
38.
39. Pearlman N.W., Meyers A.D., Sullivan W.G. Muscle fiber orientation and connective tissue content in the hypertrophied human heart // Lab. Invest. - 1982. - Vol. 46, № 2. - P. 158-164.
40.
41. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis // N. Engl. J. Med. - 1994. - Vol. 331, № 19. - P. 1286-1292.
42.
43. Lorell B.H., Carabello B.A. Left ventricular hypertrophy: pathogenesis, detection, and prognosis // Circulation. - 2000. - Vol. 102, № 4. - P. 470-479.
44.
45. Gerdts E., Oikarinen L., Palmieri V. et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study // Hypertension. - 2002. - Vol. 39, № 3. - P. 739-743.
46.
47. Psaty B.M., Manolio T.A., Kuller L.H. et al. Incidence of and risk factors for atrial fibrillation in older adults // Circulation. - 1997. - Vol. 96, № 7. - P. 2455-2461.
48.
49. Mattioli A.V., Vivoli D., Bastia E. Doppler echocardiography parameters predictive of recurrence of atrial fibrillation of different etiologic origins // J. Ultrasound. Med. - 1997. - № 16. - P. 695-698.
50.
51. Madu E.C., Baugh D.S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Baugh%20DS%22%5BAuthor%5D>., Gbadebo T.D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gbadebo%20TD%22%5BAuthor%5D>. Effect of ethnicity and hypertension on atrial conduction: evaluation with high-resolution P-wave signal averaging // Clin. Cardiol. - 2001. - Vol. 24, № 9. - P. 597-602.
52.
53. Maggioni A.P., Latini R <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Latini%20R%22%5BAuthor%5D>., Carson P.E <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Carson%20PE%22%5BAuthor%5D>. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart. J. - 2005. - Vol. 149, № 3. - P. 548-557.
54.
55. Adler A.I., Stratton I.M., Neil H.A. et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study // Br. Med. J. - 2000. - Vol. 321, № 7258. - P. 412-419.
56.
57. Shi Y., Li D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20D%22%5BAuthor%5D>., Tardif J.C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Tardif%20JC%22%5BAuthor%5D>., Nattel S <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Nattel%20S%22%5BAuthor%5D>. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure // Cardiovasc. Res. - 2002. - Vol. 54, № 2. - P. 456-461.
58.
59. Everett T.H. 4th, Li H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20H%22%5BAuthor%5D>., Mangrum J.M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Mangrum%20JM%22%5BAuthor%5D>. et al. Electrical, morphological, and ultrastructural remodeling and reverse remodeling in a canine model of chronic atrial fibrillation // Circulation. - 2000. - Vol. 102, № 12. - P. 1454-1460.
60.
61. Allessie M.A. Atrial electrophysiologic remodeling: another vicious circle? // J. Cardiovasc. Electrophysiol. - 1998. - Vol. 9, № 12. - P. 1378-1393.
62.
63. Goette A., Staack T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Staack%20T%22%5BAuthor%5D>., Rцcken C <http://www.ncbi.nlm.nih.gov/pubmed?term=%22R%C3%B6cken%20C%22%5BAuthor%5D>. et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation // J. Am. Coll. Cardiol. - 2000. - Vol. 35, № 6. - P. 1669-1677.
64.
65. Klein H.U., Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? // J. Am. Coll. Cardiol. - 2003. - Vol. 41, № 12. - P. 2205-2206.
66.
67. Аметов А.С., Демидова Т.Ю., Галиева О.Р. Ингибиторы ангиотензинпревращающего фермента в профилактике и лечении сосудистых осложнений сахарного диабета // Кардиология. - 2005. - Т. 45, № 11. - С. 109-112.
68.
69. Nilsson P., Lindholm L., Scherstén B. Hyperinsulinaemia and other metabolic disturbances in well-controlled hypertensive men and women: an epidemiological study // J. Hypertens. - 1990. - Vol. 8, № 10. - P. 953-959. 36.
70.
71. American Diabetes Association. Standards of medical care in diabetes: 2006 // Diabetes Care. - 2006. - Vol. 29 (Suppl. 1), № 11. - Р. S4-S42.
72.
73. Estasio R.O., Jeffers B.W., Hiatt W.R. et al. The effect of nisoldipine as compared with noninsulin-dependent diabetes and hypertension // N. Engl. J. Med. - 1998. - Vol. 338, № 10. - P. 645-652. 38.
74.
75. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38 // Br. Med. J. - 1998. - Vol. 317, № 7160. - P. 703-713.
76.
77. Tuomilehto J., Rastenyte D <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rastenyte%20D%22%5BAuthor%5D>., Birkenhдger W.H <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Birkenh%C3%A4ger%20WH%22%5BAuthor%5D>. et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension // N. Engl. J. Med. - 1999. - Vol. 340, № 9. - P. 677-684.
78.
79. Lievre M., Gueyffier F <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Gueyffier%20F%22%5BAuthor%5D>., Ekbom T <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Ekbom%20T%22%5BAuthor%5D>. et al. Efficacy of diuretics and beta-blockers in diabetic hypertensive patients: results from meta-analysis // Diabetes Care. - 2000. - Vol. 23 (Suppl. 2). - P. B56-B71. 41.
80.
81. PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke and transient ischemic attack / Lancet. - 2001. - Vol. 358, № 9287. - P. 1033-1041. 42.
82.
83. ACCORD Study Group, Cushman W.C., Evans G.W., Byington R.P. et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus // N. Engl. J. Med. - 2010. - Vol. 362, № 17. - P. 1575-1585.
84.
85. Pessina A.C. Target organs of individuals with diabetes caught between atrial stiffness and damage to the microcirculation // J. Hypertens. - 2007. - Vol. 25, № 1. - P. S13-S17.
86.
87. El-Atat F.A., McFarlane S.I., Sowers J.R. Diabetes, hypertension and cardiovascular derangements: Update on the pathophysiology and management // Curr. Hypertens. Rep. - 2004. - Vol. 6, № 3. - P. 215-223.
88.
89. Chen J., Muntner P., Hamm L.L. et al. The metabolic syndrome and chronic kidney disease in US Adults // Ann. Intern. Med. - 2004. - Vol. 140, № 3. - P. 167-175.
90.
91. McFarlane S.I., Banerji M., Sowers J.R. Insulin resistance and cardiovascular disease // J. Clin. Endocrinol. Metab. - 2001. - Vol. 86, № 2. - P. 713-718.
92.
93. Mancia G., Bombelli M <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bombelli%20M%22%5BAuthor%5D>., Corrao G <http://www.ncbi.nlm.nih.gov/pubmed?term=%22Corrao%20G%22%5BAuthor%5D>. et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Lolo Associazioni (PAMELA) study: daily life blood pressure, cardiac damage and prognosis // Hypertension. - 2007. - Vol. 49, № 1. - P. 40-47.
94.
95. Kendall D.M., Sobel B.E., Coulston A.M. et al. The insulin resistance syndrome and coronary artery disease // Coron. Artery Dis. - 2003. - Vol. 14, № 4. - P. 335-348.
96.
97. Sowers J.R. Insulin resistance and hypertension // Am. J. Physiol. Heart Circ. Physiol. - 2004. - Vol. 286, № 5. - P. H1597-1602.
98.
99. Ferrannini E., Buzzigoli G., Bonadonna R. et al. Insulin resistance in essential hypertension // N. Engl. J. Med. - 1987. - Vol. 317, № 6. - P. 350-357.
100.
101. Govindarajan G. et al. Obesity and hypertension: A clinical update // Molecular mechanisms in hypertension / Ed. by R. Ray, E. Schiffrin, J.R. Sowers. - London: Taylor and Francis Pub, 2006. - P. 397-406.
102.
103. Baron A.D. Insulin and the vasculature - old actors, new roles // J. Invest. Med. - 1996. - Vol. 44, № 8. - P. 406-412.
104.
105. Tooke J.E., Hannemann M.M. Adverse endothelial function and the insulin resistance syndrome // J. Intern. Med. - 2000. - Vol. 247, № 4. - P. 425-431.
106.
107. Banos G., Carvajal K., Cardoso G., Zamora J., Franco M. Vascular reactivity and effect of serum in a rat model of hypertriglyceridemia and hypertension // Am. J. Hypertens. - 1997. - Vol. 10, № 4, Pt. 1. - P. 379-388.
108.
109. Tripathy D., Mohanty P., Dhindsa S. et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects // Diabetes. - 2003. - Vol. 52, № 12. - P. 2882-2887.
110.
111. Heeringa J., van der Kuip D.A., Hofman A. et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study // Eur. Heart. J. - 2006. - Vol. 27, № 8. - P. 949-953.
112.
113. Wanahita N., Messerli F.H., Bangalore S., Gami A.S., Somers V.K., Steinberg J.S. Atrial fibrillation and obesity - results of a meta-analysis // Am. Heart. J. - 2008. - Vol. 155, № 2. - P. 310-315.
114.
115. Movahed M.R., Hashemzadeh M., Jamal M.M. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease // Int. J. Cardiol. - 2005. - Vol. 105, № 3. - P. 315-318.
116.
117. Korantzopoulos P., Kokkoris S., Kountouris E., Protopsaltis I., Siogas K., Melidonis A. Regression of paroxysmal atrial fibrillation associated with thiazolidinedione therapy // Int. J. Cardiol. - 2008. - Vol. 125, № 3. - P. e51-e53.
118.
119. Johansen O.E., Brustad E., Enger S., Tveit A. Prevalence of abnormal glucose metabolism in atrial fibrillation: A case control study in 75-year old subjects // Cardiovasc. Diabetol. - 2008. - № 7. - P. 28.
120.
121. Barriales A.V., Morís de la Tassa C., Sánchez Posada I. et al. The etiology and associated risk factors in sample of 300 patients with atrial fibrillation // Rev. Esp. Cardiol. - 1999. - Vol. 52, № 6. - P. 403.
122.
123. Kato T., Ishida S., Morooka T. et al. Postprandial hyperglycemia is a possible contributor to paroxysmal atrial fibrillation: a case report // J. Cardiol. - 2006. - Vol. 48, № 5. - P. 269-272.
124.
125. Chung M.K., Martin D.O., Sprecher D. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation // Circulation. - 2001. - Vol. 104, № 24. - P. 2886-2891.
Рецензия
Для цитирования:
Барсуков А.В., Свеклина Т.С., Таланцева М.С., Шустов С.Б. Артериальная гипертензия, сахарный диабет 2 типа и фибрилляция предсердий как самостоятельная медицинская проблема. Артериальная гипертензия. 2011;17(2):108-114. https://doi.org/10.18705/1607-419X-2011--2-
For citation:
Barsukov A.V., Sveklina T.S., Talantzeva M.S., Shustov S.B. Arterial hypertension, type 2 diabetes mellitus, and atrial fibrillation as an independent medical problem. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(2):108-114. (In Russ.) https://doi.org/10.18705/1607-419X-2011--2-